QPTFF (Quest PharmaTech) EBIT: $3.62 Mil (TTM As of Jan. 2026)


What is Quest PharmaTech EBIT?

Quest PharmaTech QPTFF EBIT is $3.62 Mil as of Jan. 2026.

Quest PharmaTech's earnings before interest and taxes (EBIT) for the three months ended in Jan. 2026 was $2.47 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jan. 2026 was $3.62 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Quest PharmaTech's annualized ROC % for the quarter that ended in Jan. 2026 was -2.94%. Quest PharmaTech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2026 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Quest PharmaTech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2026 was 98.67%.

Quest PharmaTech  (OTCPK:QPTFF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Quest PharmaTech's annualized ROC % for the quarter that ended in Jan. 2026 is calculated as:

ROC % (Q: Jan. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Oct. 2025 ) + Invested Capital (Q: Jan. 2026 ))/ count )
=-0.572 * ( 1 - 0% )/( (18.05 + 20.856)/ 2 )
=-0.572/19.453
=-2.94 %

where

Invested Capital(Q: Oct. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=17.396 - 0.182 - ( 0.041 - max(0, 0.896 - 0.06+0.041))
=18.05

Invested Capital(Q: Jan. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=20.154 - 0.239 - ( 0.01 - max(0, 0.965 - 0.024+0.01))
=20.856

Note: The Operating Income data used here is four times the quarterly (Jan. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Quest PharmaTech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Jan. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Oct. 2025  Q: Jan. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=9.892/( ( (0 + max(-0.162, 0)) + (0 + max(-0.225, 0)) )/ 2 )
=9.892/( ( 0 + 0 )/ 2 )
=9.892/0
= %

where Working Capital is:

Working Capital(Q: Oct. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.019) - (0.182 + 0 + -0.001)
=-0.162

Working Capital(Q: Jan. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.014) - (0.239 + 0 + 0)
=-0.225

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jan. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Quest PharmaTech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jan. 2026 )
=3.624/3.673
=98.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Quest PharmaTech EBIT Related Terms

Quest PharmaTech EBIT Historical Data

* Premium members only.

The historical data trend for Quest PharmaTech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Quest PharmaTech EBIT Chart

Quest PharmaTech Annual Data
Trend Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24 Jan25 Jan26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -67.36 -48.33 -2.23 -1.24 3.65

Quest PharmaTech Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.18 0.50 -0.13 0.78 2.47

QPTFF vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Quest PharmaTech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Quest PharmaTech EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Quest PharmaTech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Quest PharmaTech's EV-to-EBIT falls into.


Quest PharmaTech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.62 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $3.62 Mil mean?
Quest PharmaTech (QPTFF) has a EBIT of $3.62 Mil as of Jan. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Quest PharmaTech.
Is Quest PharmaTech's EBIT too high?
Quest PharmaTech's current EBIT is $3.62 Mil.
How does Quest PharmaTech's EBIT compare to VRTX and REGN?
Quest PharmaTech's EBIT of $3.62 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Quest PharmaTech. Quest PharmaTech's current EBIT is $3.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest PharmaTech stock overvalued right now?
Quest PharmaTech (QPTFF) has a current EBIT of $3.62 Mil. The current EBIT is $3.62 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Quest PharmaTech (QPTFF), the current EBIT is $3.62 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Quest PharmaTech Business Description

Other Exchanges QPT:Canada
Address 4342- 97 Street NW, Edmonton, AB, CAN, T6E 5R9
Quest PharmaTech Inc is developing targeted cancer therapy with its product (MAb AR9.6), under development for a novel target (truncated O-glycans on MUC16) discovered at the University of Nebraska Medical Center.